Mucinex taps nighttime market

Reckitt Benckiser this season extended its line of popular Mucinex Fast-Max products, which provide multi-symptom relief, to include a product for nighttime cold-and-flu relief in both liquid and tablet form, taking on Procter & Gamble’s NyQuil franchise.

(For the complete category review, including data, click here.)



According to Reckitt Benckiser, nighttime relief is a $600 million market in the United States, and Mucinex Fast-Max is differentiated from its competitors because it contains an active ingredient for nasal decongestion.